BridgeBio Pharma Analyst Ratings
BridgeBio Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/23/2023 | 125.39% | SVB Leerink | $23 → $19 | Maintains | Outperform |
| 11/18/2022 | 125.39% | JP Morgan | $20 → $19 | Maintains | Overweight |
| 08/24/2022 | 172.84% | Mizuho | $25 → $23 | Maintains | Buy |
| 07/26/2022 | 255.87% | SVB Leerink | $27 → $30 | Maintains | Outperform |
| 05/24/2022 | 125.39% | Goldman Sachs | $24 → $19 | Maintains | Buy |
| 05/06/2022 | 220.28% | SVB Leerink | $26 → $27 | Maintains | Outperform |
| 03/16/2022 | 160.97% | HC Wainwright & Co. | $24 → $22 | Maintains | Buy |
| 03/11/2022 | 113.52% | JP Morgan | $21 → $18 | Maintains | Overweight |
| 03/09/2022 | 208.42% | SVB Leerink | $25 → $26 | Maintains | Outperform |
| 03/04/2022 | 196.56% | SVB Leerink | $24 → $25 | Maintains | Outperform |
| 12/28/2021 | 184.7% | HC Wainwright & Co. | $88 → $24 | Maintains | Buy |
| 12/28/2021 | 184.7% | SVB Leerink | $66 → $24 | Maintains | Outperform |
| 11/19/2021 | 682.92% | SVB Leerink | $68 → $66 | Maintains | Outperform |
| 10/25/2021 | 943.89% | HC Wainwright & Co. | $87 → $88 | Maintains | Buy |
| 10/04/2021 | 706.64% | SVB Leerink | $66 → $68 | Maintains | Outperform |
| 09/10/2021 | 789.68% | B of A Securities | → $75 | Upgrades | Neutral → Buy |
| 08/06/2021 | 682.92% | SVB Leerink | $71 → $66 | Maintains | Outperform |
| 05/21/2021 | 848.99% | UBS | → $80 | Initiates Coverage On | → Buy |
| 05/07/2021 | 848.99% | Goldman Sachs | $92 → $80 | Maintains | Buy |
| 03/23/2021 | 789.68% | SVB Leerink | $67 → $75 | Maintains | Outperform |
| 03/04/2021 | 920.17% | Mizuho | $56 → $86 | Maintains | Buy |
| 02/09/2021 | 884.58% | Goldman Sachs | → $83 | Reinstates | → Buy |
| 01/11/2021 | 932.03% | HC Wainwright & Co. | $64 → $87 | Maintains | Buy |
| 12/10/2020 | 659.19% | HC Wainwright & Co. | $53 → $64 | Maintains | Buy |
| 12/04/2020 | 421.95% | SVB Leerink | $39 → $44 | Maintains | Outperform |
| 10/12/2020 | 528.71% | HC Wainwright & Co. | $50 → $53 | Maintains | Buy |
| 06/25/2020 | 350.77% | B of A Securities | → $38 | Initiates Coverage On | → Neutral |
| 05/19/2020 | 481.26% | BTIG | → $49 | Initiates Coverage On | → Buy |
| 05/14/2020 | 362.63% | SVB Leerink | $41 → $39 | Reiterates | → Outperform |
| 04/13/2020 | 493.12% | HC Wainwright & Co. | → $50 | Initiates Coverage On | → Buy |
| 03/03/2020 | 410.08% | JP Morgan | $38 → $43 | Maintains | Overweight |
| 02/19/2020 | 504.98% | Mizuho | → $51 | Initiates Coverage On | → Buy |
| 07/26/2019 | 327.05% | Raymond James | → $36 | Initiates Coverage On | → Outperform |
| 07/22/2019 | 350.77% | JP Morgan | → $38 | Initiates Coverage On | → Overweight |
| 07/22/2019 | 350.77% | Jefferies | → $38 | Initiates Coverage On | → Buy |
| 07/22/2019 | 303.32% | SVB Leerink | → $34 | Initiates Coverage On | → Outperform |
| 07/22/2019 | 398.22% | Goldman Sachs | → $42 | Initiates Coverage On | → Buy |
| 07/22/2019 | 493.12% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
| 07/22/2019 | 481.26% | BMO Capital | → $49 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 01/23/2023 | 125.39% | SVB Leerink | $23 → $19 | 維護 | 跑贏大盤 |
| 11/18/2022 | 125.39% | 摩根大通 | $20 → $19 | 維護 | 超重 |
| 08/24/2022 | 172.84% | 瑞穗 | $25 → $23 | 維護 | 買 |
| 07/26/2022 | 255.87% | SVB Leerink | $27 → $30 | 維護 | 跑贏大盤 |
| 05/24/2022 | 125.39% | 高盛 | $24 → $19 | 維護 | 買 |
| 05/06/2022 | 220.28% | SVB Leerink | $26 → $27 | 維護 | 跑贏大盤 |
| 03/16/2022 | 160.97% | HC Wainwright公司 | $24 → $22 | 維護 | 買 |
| 03/11/2022 | 113.52% | 摩根大通 | $21 → $18 | 維護 | 超重 |
| 03/09/2022 | 208.42% | SVB Leerink | $25 → $26 | 維護 | 跑贏大盤 |
| 03/04/2022 | 196.56% | SVB Leerink | $24 → $25 | 維護 | 跑贏大盤 |
| 12/28/2021 | 184.7% | HC Wainwright公司 | $88 → $24 | 維護 | 買 |
| 12/28/2021 | 184.7% | SVB Leerink | $66 → $24 | 維護 | 跑贏大盤 |
| 11/19/2021 | 682.92% | SVB Leerink | $68 → $66 | 維護 | 跑贏大盤 |
| 10/25/2021 | 943.89% | HC Wainwright公司 | $87 → $88 | 維護 | 買 |
| 10/04/2021 | 706.64% | SVB Leerink | $66 → $68 | 維護 | 跑贏大盤 |
| 09/10/2021 | 789.68% | B of A證券 | → $75 | 升級 | 中性→購買 |
| 08/06/2021 | 682.92% | SVB Leerink | $71 → $66 | 維護 | 跑贏大盤 |
| 05/21/2021 | 848.99% | 瑞銀集團 | → $80 | 開始承保 | →購買 |
| 05/07/2021 | 848.99% | 高盛 | $92 → $80 | 維護 | 買 |
| 03/23/2021 | 789.68% | SVB Leerink | $67 → $75 | 維護 | 跑贏大盤 |
| 03/04/2021 | 920.17% | 瑞穗 | $56 → $86 | 維護 | 買 |
| 02/09/2021 | 884.58% | 高盛 | → $83 | 恢復 | →購買 |
| 01/11/2021 | 932.03% | HC Wainwright公司 | $64 → $87 | 維護 | 買 |
| 12/10/2020 | 659.19% | HC Wainwright公司 | $53 → $64 | 維護 | 買 |
| 12/04/2020 | 421.95% | SVB Leerink | $39 → $44 | 維護 | 跑贏大盤 |
| 10/12/2020 | 528.71% | HC Wainwright公司 | $50 → $53 | 維護 | 買 |
| 06/25/2020 | 350.77% | B of A證券 | → $38 | 開始承保 | →中性 |
| 05/19/2020 | 481.26% | BTIG | → $49 | 開始承保 | →購買 |
| 05/14/2020 | 362.63% | SVB Leerink | $41 → $39 | 重申 | →跑贏大盤 |
| 04/13/2020 | 493.12% | HC Wainwright公司 | → $50 | 開始承保 | →購買 |
| 03/03/2020 | 410.08% | 摩根大通 | $38 → $43 | 維護 | 超重 |
| 02/19/2020 | 504.98% | 瑞穗 | → $51 | 開始承保 | →購買 |
| 07/26/2019 | 327.05% | 雷蒙德·詹姆斯 | → $36 | 開始承保 | →跑贏大盤 |
| 07/22/2019 | 350.77% | 摩根大通 | → $38 | 開始承保 | →超重 |
| 07/22/2019 | 350.77% | 傑富瑞 | → $38 | 開始承保 | →購買 |
| 07/22/2019 | 303.32% | SVB Leerink | → $34 | 開始承保 | →跑贏大盤 |
| 07/22/2019 | 398.22% | 高盛 | → $42 | 開始承保 | →購買 |
| 07/22/2019 | 493.12% | 派珀·桑德勒 | → $50 | 開始承保 | →超重 |
| 07/22/2019 | 481.26% | 蒙特利爾銀行資本 | → $49 | 開始承保 | →跑贏大盤 |
What is the target price for BridgeBio Pharma (BBIO)?
BridgeBio Pharma(BBIO)的目標價是多少？
The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by SVB Leerink on January 23, 2023. The analyst firm set a price target for $19.00 expecting BBIO to rise to within 12 months (a possible 125.39% upside). 10 analyst firms have reported ratings in the last year.
BVB Leerink於2023年1月23日報道了BridgeBio Pharma(納斯達克：BBIO)的最新目標價。這家分析公司將目標價定為19美元，預計BBIO將在12個月內上漲(漲幅可能為125.39)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for BridgeBio Pharma (BBIO)?
BridgeBio Pharma(BBIO)的最新分析師評級是多少？
The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by SVB Leerink, and BridgeBio Pharma maintained their outperform rating.
對BridgeBio Pharma(納斯達克：BBIO)的最新分析師評級由SVB Leerink提供，BridgeBio Pharma維持其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?
BridgeBio Pharma(BBIO)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on January 23, 2023 so you should expect the next rating to be made available sometime around January 23, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公開財務報表，與BridgeBio Pharma的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。BridgeBio Pharma的上一次評級是在2023年1月23日提交的，所以你應該預計下一次評級將在2024年1月23日左右的某個時候提供。
Is the Analyst Rating BridgeBio Pharma (BBIO) correct?
分析師對BridgeBio Pharma(BBIO)的評級正確嗎？
While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a maintained with a price target of $23.00 to $19.00. The current price BridgeBio Pharma (BBIO) is trading at is $8.43, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的BridgeBio Pharma(BBIO)評級維持不變，目標價在23.00美元至19.00美元之間。目前BridgeBio Pharma的交易價格為8.43美元，超出了分析師的預測區間。